MiddleBrook Pharmaceuticals Announces Board Of Directors Resignations

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that James H. Cavanaugh, Ph.D., Martin A. Vogelbaum and Harold R. Werner have resigned from the Company’s Board of Directors effective immediately.

“We thank Jim, Martin and Hal for their contributions to MiddleBrook as Board members,” said Dave Becker, acting president and chief executive officer of MiddleBrook.

About MiddleBrook Pharmaceuticals

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) currently markets MOXATAG, the first and only FDA-approved once-daily amoxicillin, and KEFLEX (cephalexin, USP), the immediate-release brand of cephalexin. MiddleBrook’s proprietary delivery technology, PULSYS, enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., are MiddleBrook’s trademarks and have been registered in the U.S. Patent and Trademark Office or are the subject of pending U.S. trademarks applications. References to “we,” ‘‘us,” “our,” ‘‘MiddleBrook,” or the “Company,” refer to MiddleBrook Pharmaceuticals, Inc., and its subsidiaries.

>To order reprints of this article, click here: Reprints